Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV6 | Q9H1D0 | 5/20 | 0.52 |
| ▸ | ORAI1 | Q96D31 | 4/20 | 0.52 |
| ▸ | ORAI2 | Q96SN7 | 4/20 | 0.52 |
| ▸ | ORAI3 | Q9BRQ5 | 4/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 2/20 | 0.39 |
| ▸ | CES1 | P23141 | 2/20 | 0.39 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2406407 | 0.82 | ORAI1 (0.42) | TRPV6ORAI1ORAI2ORAI3CA12 | |
| SCHEMBL124847 | 0.81 | CA1 (0.45) | TRPV6ORAI1ORAI2ORAI3CA12 | |
| SCHEMBL16812679 | 0.77 | CA12 (0.41) | TRPV6ORAI1ORAI2ORAI3CA12 | |
| SCHEMBL125969 | 0.73 | CA12 (0.42) | TRPV6ORAI1ORAI2ORAI3CA12 | |
| SCHEMBL1804144 | 0.73 | ORAI1 (0.43) | TRPV6ORAI1ORAI2ORAI3CA1 | |
| SCHEMBL1493119 | 0.71 | CA12 (0.40) | CA12CA1CA9CES2CES1 | |
| SCHEMBL29229465 | 0.71 | CA12 (0.40) | CA12CA1CA9CES2CES1 | |
| SCHEMBL24109422 | 0.71 | CA12 (0.36) | TRPV6ORAI1ORAI2ORAI3CA12 | |
| SCHEMBL28258396 | 0.71 | CA12 (0.36) | TRPV6ORAI1ORAI2ORAI3CA12 | |
| SCHEMBL24426677 | 0.71 | CES2 (0.37) | TRPV6ORAI1ORAI2ORAI3CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853424-B2 | Protein cross-linking inhibitor | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-10-07 | — | — | US | disclosed |
| US-8853424-B2 | Protein cross-linking inhibitor | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-01 | — | — | US | disclosed |
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-01 | — | — | US | disclosed |
| WO-2010018837-A2 | PROTEIN CROSS-LINKING INHIBITOR | 独立行政法人科学技術振興機構 (JP) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010018836-A2 | POLYGLUTAMINE AGGREGATION INHIBITOR | 独立行政法人科学技術振興機構 (JP) | 2010-02-18 | — | — | WO | disclosed |
| US-6933354-B2 | Aluminoboronate activators for single-site olefin polymerization catalysts | EQUISTAR CHEMICALS, LP (US) | 2005-08-23 | — | — | US | disclosed |
| EP-1392738-B1 | ALUMINOBORANATE ACTIVATORS FOR SINGLE-SITE OLEFIN POLYMERIZATION CATALYSTS | EQUISTAR CHEM LP (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20040181017-A1 | Aluminoboronate activators for single-site olefin polymerization catalysts | EQUISTAR CHEMICALS, LP | 2004-09-16 | — | — | US | disclosed |
| US-6759361-B2 | A SUPPORTED CATALYTIC ORGANOMETALLIC COMPLEX OF A TRANSITION METAL, INDENOINDOLYL LIGAND AND THE ACTIVATOR, A REACTION PRODUCT OF ALKYLALUMINUM COMPOUND AND AN ORGANIC-BORONIC ACID; NARROW MOLECULAR WEIGHT DISTRIBUTION; LOW DENSITY | EQUISTAR CHEMICALS, LP | 2004-07-06 | — | — | US | disclosed |
| EP-1392738-A1 | ALUMINOBORANATE ACTIVATORS FOR SINGLE-SITE OLEFIN POLYMERIZATION CATALYSTS | Equistar Chemicals, LP (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030004052-A1 | Aluminoboronate activators for single-site olefin polymerization catalysts | EQUISTAR CHEMICALS, LP | 2003-01-02 | — | — | US | disclosed |
| WO-2002098930-A1 | ALUMINOBORANATE ACTIVATORS FOR SINGLE-SITE OLEFIN POLYMERIZATION CATALYSTS | EQUISTAR CHEMICALS, LP (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | BAZ2B, PRMT1, BRIX1 | TRPV6 4868/4885ORAI1 4605/4885ORAI2 3906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.